Viewing Study NCT01719380



Ignite Creation Date: 2024-05-06 @ 1:02 AM
Last Modification Date: 2024-10-26 @ 10:58 AM
Study NCT ID: NCT01719380
Status: COMPLETED
Last Update Posted: 2021-06-23
First Post: 2012-10-30

Brief Title: Study of LGX818 and Cetuximab or LGX818 BYL719 and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
Sponsor: Pfizer
Organization: Pfizer

Study Overview

Official Title: A Phase IbII Multi-center Open-label Dose Escalation Study of LGX818 and Cetuximab or LGX818 BYL719 and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer
Status: COMPLETED
Status Verified Date: 2021-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study will assess the safety and efficacy of LGX818 when combined with cetuximab or combined with cetuximab and BYL719 in patients with BRAF mutant metastatic colorectal cancer
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
2012-002138-35 EUDRACT_NUMBER Alias Study Number None
C4221002 OTHER None None